{"id":757359,"date":"2023-05-10T11:46:07","date_gmt":"2023-05-10T15:46:07","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/dr-reddys-q4-fy23-financial-results\/"},"modified":"2023-05-10T11:46:07","modified_gmt":"2023-05-10T15:46:07","slug":"dr-reddys-q4-fy23-financial-results","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/dr-reddys-q4-fy23-financial-results\/","title":{"rendered":"Dr. Reddy\u2019s Q4 & FY23 Financial Results"},"content":{"rendered":"

<\/p>\n

Dr. Reddy\u2019s Q4 & FY23 Financial Results<\/span><\/b><\/p>\n

HYDERABAD, India–(BUSINESS WIRE<\/a>)–
\nDr. Reddy\u2019s Laboratories Ltd. (BSE: 500124 | NSE: DRREDDY | NYSE: RDY | NSEIFSC: DRREDDY) today announced its consolidated financial results for the fourth quarter and full year ended March 31, 2023. The information mentioned in this release is on the basis of consolidated financial statements under International Financial Reporting Standards (IFRS).<\/p>\n

This press release features multimedia. View the full release here: https:\/\/www.businesswire.com\/news\/home\/20230510005650\/en\/<\/a><\/p>\n

\"Q4<\/p>\n

Q4 FY23 Sales Mix (Graphic: Business Wire)<\/p>\n<\/div>\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n
Q4 Performance Summary<\/span><\/b><\/td>\n\nFY23 Performance Summary<\/span><\/b><\/td>\n<\/tr>\n
\n\n\u00a0<\/td>\n<\/tr>\n
Rs. 6,297 Cr<\/i><\/b><\/td>\n\nRs. 24,588 Cr<\/i><\/b><\/td>\n<\/tr>\n
Revenue<\/i><\/b><\/td>\n\nRevenue<\/i><\/b><\/td>\n<\/tr>\n
[Up: 16% YoY; Down 7% QoQ]<\/i><\/td>\n\n[Up: 15% YoY]<\/i><\/td>\n<\/tr>\n
\n\n\u00a0<\/td>\n<\/tr>\n
\n

57.2%<\/i><\/b><\/p>\n<\/td>\n

\n\n

56.7%<\/i><\/b><\/p>\n<\/td>\n<\/tr>\n

Gross Margin<\/i><\/b><\/td>\n\nGross Margin<\/i><\/b><\/td>\n<\/tr>\n
[Q4 FY22: 52.9%; Q3 FY23: 59.2%]<\/i><\/td>\n\n[FY22: 53.1%]<\/i><\/td>\n<\/tr>\n
\n\n\u00a0<\/td>\n<\/tr>\n
Rs. 1,799 Cr<\/i><\/b><\/td>\n\nRs. 6,803 Cr<\/i><\/b><\/td>\n<\/tr>\n
SGNA expenses<\/i><\/b><\/td>\n\nSGNA expenses<\/i><\/b><\/td>\n<\/tr>\n
[28.6% of Revenues]<\/i><\/td>\n\n[27.7% of Revenues]<\/i><\/td>\n<\/tr>\n
\n\n\u00a0<\/td>\n<\/tr>\n
Rs. 537 Cr<\/i><\/b><\/td>\n\nRs. 1,938 Cr<\/i><\/b><\/td>\n<\/tr>\n
R&D expenses<\/i><\/b><\/td>\n\nR&D expenses<\/i><\/b><\/td>\n<\/tr>\n
[8.5% of Revenues]<\/i><\/td>\n\n[7.9% of Revenues]<\/i><\/td>\n<\/tr>\n
\n\n\u00a0<\/td>\n<\/tr>\n
Rs. 1,631 Cr<\/i><\/b><\/td>\n\nRs. 7,308 Cr<\/i><\/b><\/td>\n<\/tr>\n
EBITDA<\/i><\/b><\/td>\n\nEBITDA<\/i><\/b><\/td>\n<\/tr>\n
[25.9% of Revenues; Up: 26% YoY; Down: 17% QoQ]<\/i><\/td>\n\n[29.7% of Revenues; Up: 42% YoY]<\/i><\/td>\n<\/tr>\n
\n\n\u00a0<\/td>\n<\/tr>\n
Rs. 1,326 Cr*<\/i><\/b><\/td>\n\nRs. 6,037 Cr*<\/i><\/b><\/td>\n<\/tr>\n
Profit before Tax<\/i><\/b><\/td>\n\nProfit before Tax<\/i><\/b><\/td>\n<\/tr>\n
[Up: 434% YoY; Down: 19% QoQ]<\/i><\/td>\n\n[Up: 87% YoY]<\/i><\/td>\n<\/tr>\n
\n\n\u00a0<\/td>\n<\/tr>\n
Rs. 959 Cr<\/i><\/b><\/td>\n\nRs. 4,507 Cr<\/i><\/b><\/td>\n<\/tr>\n
Profit after Tax<\/i><\/b><\/td>\n\nProfit after Tax<\/i><\/b><\/td>\n<\/tr>\n
[Up: 996% YoY; Down: 23% QoQ]<\/i><\/td>\n\n[Up: 91% YoY]<\/i><\/td>\n<\/tr>\n
\n

\n* Excluding impairments in current & previous periods, Q4 FY 23 PBT is Rs. 1,380 Cr (growth of 38% YoY) and FY 23 PBT is Rs. 6,107 Cr (growth of 53% YoY)<\/p>\n<\/td>\n<\/tr>\n<\/table>\n

Commenting on the results, Co-Chairman & MD, G V Prasad said: \u201cFY 23 has been a year of record sales, profits and cash flow, driven by our performance in US Generics. We progressed well in our productivity and sustainability agenda. We will continue to deliver on our purpose, invest in growth drivers and promote a culture that is innovative and collaborative ensuring the future of our business.\u201d<\/i><\/p>\n

All amounts in millions, except EPS. All US dollar amounts based on convenience translation rate of 1 USD = Rs. 82.19<\/i><\/p>\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n
\n

Dr. Reddy\u2019s Laboratories Limited and Subsidiaries<\/span><\/b><\/p>\n<\/td>\n<\/tr>\n

<\/tr>\n
\n

Consolidated Income Statement<\/b><\/p>\n<\/td>\n<\/tr>\n

\n\n\n\n\n\u00a0<\/td>\n<\/tr>\n
\n

Particulars<\/b><\/p>\n<\/td>\n

\n

Q4 FY23<\/b><\/p>\n<\/td>\n

\n

Q4 FY22<\/b><\/p>\n<\/td>\n

\n

YoY
\n
Gr %<\/b><\/p>\n<\/td>\n

\n

Q3 FY23<\/b><\/p>\n<\/td>\n

\n

QoQ
\n
Gr%<\/b><\/p>\n<\/td>\n<\/tr>\n

\n

($)<\/b><\/p>\n<\/td>\n

\n

(Rs.)<\/b><\/p>\n<\/td>\n

\n

($)<\/b><\/p>\n<\/td>\n

\n

(Rs.)<\/b><\/p>\n<\/td>\n

\n

($)<\/b><\/p>\n<\/td>\n

\n

(Rs.)<\/b><\/p>\n<\/td>\n<\/tr>\n

\n

Revenues<\/b><\/p>\n<\/td>\n

\n

766<\/b><\/p>\n<\/td>\n

\n

62,968<\/b><\/p>\n<\/td>\n

\n

661<\/b><\/p>\n<\/td>\n

\n

54,368<\/b><\/p>\n<\/td>\n

\n

16<\/b><\/p>\n<\/td>\n

\n

824<\/b><\/p>\n<\/td>\n

\n

67,700<\/b><\/p>\n<\/td>\n

\n

(7)<\/b><\/p>\n<\/td>\n<\/tr>\n

\n

\nCost of Revenues<\/p>\n<\/td>\n

\n

\n328<\/p>\n<\/td>\n

\n

\n26,971<\/p>\n<\/td>\n

\n

\n312<\/p>\n<\/td>\n

\n

\n25,625<\/p>\n<\/td>\n

\n

\n5<\/p>\n<\/td>\n

\n

\n336<\/p>\n<\/td>\n

\n

\n27,607<\/p>\n<\/td>\n

\n

\n(2)<\/p>\n<\/td>\n<\/tr>\n

\n

Gross Profit<\/b><\/p>\n<\/td>\n

\n

438<\/b><\/p>\n<\/td>\n

\n

35,997<\/b><\/p>\n<\/td>\n

\n

350<\/b><\/p>\n<\/td>\n

\n

28,743<\/b><\/p>\n<\/td>\n

\n

25<\/b><\/p>\n<\/td>\n

\n

488<\/b><\/p>\n<\/td>\n

\n

40,093<\/b><\/p>\n<\/td>\n

\n

(10)<\/b><\/p>\n<\/td>\n<\/tr>\n

\n

Operating Expenses<\/b><\/p>\n<\/td>\n

\n

\n\u00a0<\/p>\n<\/td>\n

\n

\n\u00a0<\/p>\n<\/td>\n

\n

\n\u00a0<\/p>\n<\/td>\n

\n

\n\u00a0<\/p>\n<\/td>\n

\n

\n\u00a0<\/p>\n<\/td>\n

\n

\n\u00a0<\/p>\n<\/td>\n

\n

\n\u00a0<\/p>\n<\/td>\n

\n

\n\u00a0<\/p>\n<\/td>\n<\/tr>\n

\n

\nSelling, General & Administrative expenses<\/p>\n<\/td>\n

\n

\n219<\/p>\n<\/td>\n

\n

\n17,992<\/p>\n<\/td>\n

\n

\n191<\/p>\n<\/td>\n

\n

\n15,674<\/p>\n<\/td>\n

\n

\n15<\/p>\n<\/td>\n

\n

\n219<\/p>\n<\/td>\n

\n

\n17,981<\/p>\n<\/td>\n

\n

\n0<\/p>\n<\/td>\n<\/tr>\n

\n

\nResearch and Development expenses<\/p>\n<\/td>\n

\n

\n65<\/p>\n<\/td>\n

\n

\n5,366<\/p>\n<\/td>\n

\n

\n53<\/p>\n<\/td>\n

\n

\n4,326<\/p>\n<\/td>\n

\n

\n24<\/p>\n<\/td>\n

\n

\n59<\/p>\n<\/td>\n

\n

\n4,821<\/p>\n<\/td>\n

\n

\n11<\/p>\n<\/td>\n<\/tr>\n

\n

\nImpairment of non-current assets<\/p>\n<\/td>\n

\n

\n7<\/p>\n<\/td>\n

\n

\n540<\/p>\n<\/td>\n

\n

\n91<\/p>\n<\/td>\n

\n

\n7,515<\/p>\n<\/td>\n

\n

\n(93)<\/p>\n<\/td>\n

\n

\n2<\/p>\n<\/td>\n

\n

\n134<\/p>\n<\/td>\n

\n

\n303<\/p>\n<\/td>\n<\/tr>\n

\n

\nOther operating (income)\/expense<\/p>\n<\/td>\n

\n

\n(3)<\/p>\n<\/td>\n

\n

\n(281)<\/p>\n<\/td>\n

\n

\n(4)<\/p>\n<\/td>\n

\n

\n(291)<\/p>\n<\/td>\n

\n

\n(3)<\/p>\n<\/td>\n

\n

\n9<\/p>\n<\/td>\n

\n

\n732<\/p>\n<\/td>\n

\n

\n(138)<\/p>\n<\/td>\n<\/tr>\n

\n

Results from operating activities<\/b><\/p>\n<\/td>\n

\n

151<\/b><\/p>\n<\/td>\n

\n

12,380<\/b><\/p>\n<\/td>\n

\n

18<\/b><\/p>\n<\/td>\n

\n

1,519<\/b><\/p>\n<\/td>\n

\n

715<\/b><\/p>\n<\/td>\n

\n

200<\/b><\/p>\n<\/td>\n

\n

16,425<\/b><\/p>\n<\/td>\n

\n

(25)<\/b><\/p>\n<\/td>\n<\/tr>\n

\n

\nNet finance (income)\/expense<\/p>\n<\/td>\n

\n

\n(10)<\/p>\n<\/td>\n

\n

\n(799)<\/p>\n<\/td>\n

\n

\n(10)<\/p>\n<\/td>\n

\n

\n(859)<\/p>\n<\/td>\n

\n

\n(7)<\/p>\n<\/td>\n

\n

\n2<\/p>\n<\/td>\n

\n

\n139<\/p>\n<\/td>\n

\n

\n(675)<\/p>\n<\/td>\n<\/tr>\n

\n

\nShare of profit of equity accounted investees<\/p>\n<\/td>\n

\n

\n(1)<\/p>\n<\/td>\n

\n

\n(76)<\/p>\n<\/td>\n

\n

\n(1)<\/p>\n<\/td>\n

\n

\n(105)<\/p>\n<\/td>\n

\n

\n(28)<\/p>\n<\/td>\n

\n

\n(1)<\/p>\n<\/td>\n

\n

\n(60)<\/p>\n<\/td>\n

\n

\n27<\/p>\n<\/td>\n<\/tr>\n

\n

Profit before income tax<\/b><\/p>\n<\/td>\n

\n

161<\/b><\/p>\n<\/td>\n

\n

13,255<\/b><\/p>\n<\/td>\n

\n

30<\/b><\/p>\n<\/td>\n

\n

2,483<\/b><\/p>\n<\/td>\n

\n

434<\/b><\/p>\n<\/td>\n

\n

199<\/b><\/p>\n<\/td>\n

\n

16,346<\/b><\/p>\n<\/td>\n

\n

(19)<\/b><\/p>\n<\/td>\n<\/tr>\n

\n

\nIncome tax expense<\/p>\n<\/td>\n

\n

\n45<\/p>\n<\/td>\n

\n

\n3,663<\/p>\n<\/td>\n

\n

\n20<\/p>\n<\/td>\n

\n

\n1,608<\/p>\n<\/td>\n

\n

\n128<\/p>\n<\/td>\n

\n

\n47<\/p>\n<\/td>\n

\n

\n3,875<\/p>\n<\/td>\n

\n

\n(5)<\/p>\n<\/td>\n<\/tr>\n

\n

Profit for the period<\/b><\/p>\n<\/td>\n

\n

117<\/b><\/p>\n<\/td>\n

\n

9,592<\/b><\/p>\n<\/td>\n

\n

11<\/b><\/p>\n<\/td>\n

\n

875<\/b><\/p>\n<\/td>\n

\n

996<\/b><\/p>\n<\/td>\n

\n

152<\/b><\/p>\n<\/td>\n

\n

12,471<\/b><\/p>\n<\/td>\n

\n

(23)<\/b><\/p>\n<\/td>\n<\/tr>\n

\n\n

\n\u00a0<\/p>\n<\/td>\n

\n

\n\u00a0<\/p>\n<\/td>\n

\n

\n\u00a0<\/p>\n<\/td>\n

\n

\n\u00a0<\/p>\n<\/td>\n

\n

\n\u00a0<\/p>\n<\/td>\n

\n

\n\u00a0<\/p>\n<\/td>\n

\n

\n\u00a0<\/p>\n<\/td>\n

\n

\n\u00a0<\/p>\n<\/td>\n<\/tr>\n

\n

Diluted Earnings Per Share (EPS)<\/b><\/p>\n<\/td>\n

\n

0.70<\/b><\/p>\n<\/td>\n

\n

57.62<\/b><\/p>\n<\/td>\n

\n

0.06<\/b><\/p>\n<\/td>\n

\n

5.26<\/b><\/p>\n<\/td>\n

\n

995<\/b><\/p>\n<\/td>\n

\n

0.91<\/b><\/p>\n<\/td>\n

\n

74.95<\/b><\/p>\n<\/td>\n

\n

(23)<\/b><\/p>\n<\/td>\n<\/tr>\n<\/table>\n\n\n\n\n\n\n\n\n
\n

As % to revenues<\/b><\/p>\n<\/td>\n

\n\n

Q4 FY23<\/b><\/p>\n<\/td>\n

\n\n

Q4 FY22<\/b><\/p>\n<\/td>\n

\n\n\n

Q3 FY23<\/b><\/p>\n<\/td>\n<\/tr>\n

\n

\nGross Profit<\/p>\n<\/td>\n

\n\n

\n57.2<\/p>\n<\/td>\n

\n

\n\u00a0<\/p>\n<\/td>\n

\n

\n52.9<\/p>\n<\/td>\n

\n

\n\u00a0<\/p>\n<\/td>\n

\n

\n\u00a0<\/p>\n<\/td>\n

\n

\n59.2<\/p>\n<\/td>\n<\/tr>\n

\n

\nSG&A<\/p>\n<\/td>\n

\n\n

\n28.6<\/p>\n<\/td>\n

\n

\n\u00a0<\/p>\n<\/td>\n

\n

\n28.8<\/p>\n<\/td>\n

\n

\n\u00a0<\/p>\n<\/td>\n

\n

\n\u00a0<\/p>\n<\/td>\n

\n

\n26.6<\/p>\n<\/td>\n<\/tr>\n

\n

\nR&D<\/p>\n<\/td>\n

\n\n

\n8.5<\/p>\n<\/td>\n

\n

\n\u00a0<\/p>\n<\/td>\n

\n

\n8.0<\/p>\n<\/td>\n

\n

\n\u00a0<\/p>\n<\/td>\n

\n

\n\u00a0<\/p>\n<\/td>\n

\n

\n7.1<\/p>\n<\/td>\n<\/tr>\n

\n

\nEBITDA<\/p>\n<\/td>\n

\n\n

\n25.9<\/p>\n<\/td>\n

\n

\n\u00a0<\/p>\n<\/td>\n

\n

\n23.9<\/p>\n<\/td>\n

\n

\n\u00a0<\/p>\n<\/td>\n

\n

\n\u00a0<\/p>\n<\/td>\n

\n

\n29.0<\/p>\n<\/td>\n<\/tr>\n

\n

\nPBT<\/p>\n<\/td>\n

\n\n

\n21.1<\/p>\n<\/td>\n

\n

\n\u00a0<\/p>\n<\/td>\n

\n

\n4.6<\/p>\n<\/td>\n

\n

\n\u00a0<\/p>\n<\/td>\n

\n

\n\u00a0<\/p>\n<\/td>\n

\n

\n24.1<\/p>\n<\/td>\n<\/tr>\n

\n

\nPAT<\/p>\n<\/td>\n

\n\n

\n15.2<\/p>\n<\/td>\n

\n

\n\u00a0<\/p>\n<\/td>\n

\n

\n1.6<\/p>\n<\/td>\n

\n

\n\u00a0<\/p>\n<\/td>\n

\n

\n\u00a0<\/p>\n<\/td>\n

\n

\n18.4<\/p>\n<\/td>\n<\/tr>\n<\/table>\n\n\n\n\n\n\n\n\n\n\n\n\n
\n

EBITDA Computation<\/b><\/p>\n<\/td>\n<\/tr>\n

\n\n\n\n\n\u00a0<\/td>\n<\/tr>\n
\n

Particulars<\/b><\/p>\n<\/td>\n

\n

Q4 FY23<\/b><\/p>\n<\/td>\n

\n\n

Q4 FY22<\/b><\/p>\n<\/td>\n

\n\n

Q3 FY23<\/b><\/p>\n<\/td>\n<\/tr>\n

\n

($)<\/b><\/p>\n<\/td>\n

\n

(Rs.)<\/b><\/p>\n<\/td>\n

\n\n

($)<\/b><\/p>\n<\/td>\n

\n

(Rs.)<\/b><\/p>\n<\/td>\n

\n\n

($)<\/b><\/p>\n<\/td>\n

\n

(Rs.)<\/b><\/p>\n<\/td>\n<\/tr>\n

\n

Profit before Income Tax<\/b><\/p>\n<\/td>\n

\n

\n161<\/p>\n<\/td>\n

\n

\n13,255<\/p>\n<\/td>\n

\n

\n\u00a0<\/p>\n<\/td>\n

\n

\n30<\/p>\n<\/td>\n

\n

\n2,483<\/p>\n<\/td>\n

\n

\n\u00a0<\/p>\n<\/td>\n

\n

\n199<\/p>\n<\/td>\n

\n

\n16,346<\/p>\n<\/td>\n<\/tr>\n

\n

\nInterest (income) \/ expense – Net*<\/p>\n<\/td>\n

\n

\n(8)<\/p>\n<\/td>\n

\n

\n(673)<\/p>\n<\/td>\n

\n

\n\u00a0<\/p>\n<\/td>\n

\n

\n0<\/p>\n<\/td>\n

\n

\n24<\/p>\n<\/td>\n

\n

\n\u00a0<\/p>\n<\/td>\n

\n

\n(1)<\/p>\n<\/td>\n

\n

\n(93)<\/p>\n<\/td>\n<\/tr>\n

\n

\nDepreciation<\/p>\n<\/td>\n

\n

\n27<\/p>\n<\/td>\n

\n

\n2,213<\/p>\n<\/td>\n

\n

\n\u00a0<\/p>\n<\/td>\n

\n

\n25<\/p>\n<\/td>\n

\n

\n2,039<\/p>\n<\/td>\n

\n

\n\u00a0<\/p>\n<\/td>\n

\n

\n27<\/p>\n<\/td>\n

\n

\n2,245<\/p>\n<\/td>\n<\/tr>\n

\n

\nAmortization<\/p>\n<\/td>\n

\n

\n12<\/p>\n<\/td>\n

\n

\n977<\/p>\n<\/td>\n

\n

\n\u00a0<\/p>\n<\/td>\n

\n

\n11<\/p>\n<\/td>\n

\n

\n920<\/p>\n<\/td>\n

\n

\n\u00a0<\/p>\n<\/td>\n

\n

\n12<\/p>\n<\/td>\n

\n

\n1,026<\/p>\n<\/td>\n<\/tr>\n

\n

\nImpairment<\/p>\n<\/td>\n

\n

\n7<\/p>\n<\/td>\n

\n

\n540<\/p>\n<\/td>\n

\n

\n\u00a0<\/p>\n<\/td>\n

\n

\n91<\/p>\n<\/td>\n

\n

\n7,515<\/p>\n<\/td>\n

\n

\n\u00a0<\/p>\n<\/td>\n

\n

\n2<\/p>\n<\/td>\n

\n

\n134<\/p>\n<\/td>\n<\/tr>\n

\n

EBITDA<\/b><\/p>\n<\/td>\n

\n

198<\/b><\/p>\n<\/td>\n

\n

16,312<\/b><\/p>\n<\/td>\n

\n

\n\u00a0<\/p>\n<\/td>\n

\n

158<\/b><\/p>\n<\/td>\n

\n

12,980<\/b><\/p>\n<\/td>\n

\n

\n\u00a0<\/p>\n<\/td>\n

\n

239<\/b><\/p>\n<\/td>\n

\n

19,658<\/b><\/p>\n<\/td>\n<\/tr>\n

\n

* Includes income from Investments<\/i><\/p>\n<\/td>\n<\/tr>\n<\/table>\n

All amounts in millions, except EPS. All US dollar amounts based on convenience translation rate of 1 USD = Rs. 82.19<\/i><\/p>\n\n\n\n\n\n\n\n\n\n\n\n\n\n
\n

Revenue Mix by Segment<\/b><\/p>\n<\/td>\n<\/tr>\n

\n\n\n\n\n\u00a0<\/td>\n<\/tr>\n
\n

Segment<\/b><\/p>\n<\/td>\n

\n

Q4 FY23<\/b><\/p>\n<\/td>\n

\n

Q4 FY22<\/b><\/p>\n<\/td>\n

\n

YoY
\n
Gr %<\/b><\/p>\n<\/td>\n

\n

Q3 FY23<\/b><\/p>\n<\/td>\n

\n

QoQ
\n
Gr %<\/b><\/p>\n<\/td>\n<\/tr>\n

\n

(Rs.)<\/b><\/p>\n<\/td>\n

\n

(Rs.)<\/b><\/p>\n<\/td>\n

\n

(Rs.)<\/b><\/p>\n<\/td>\n<\/tr>\n

\n

Global Generics<\/b><\/p>\n<\/td>\n

\n

54,257<\/b><\/p>\n<\/td>\n

\n

46,118<\/b><\/p>\n<\/td>\n

\n

18<\/b><\/p>\n<\/td>\n

\n

59,241<\/b><\/p>\n<\/td>\n

\n

(8)<\/b><\/p>\n<\/td>\n<\/tr>\n

\n

\nNorth America<\/p>\n<\/td>\n

\n

\n25,321<\/p>\n<\/td>\n

\n

\n19,971<\/p>\n<\/td>\n

\n

\n27<\/p>\n<\/td>\n

\n

\n30,567<\/p>\n<\/td>\n

\n

\n(17)<\/p>\n<\/td>\n<\/tr>\n

\n

\nEurope<\/p>\n<\/td>\n

\n

\n4,960<\/p>\n<\/td>\n

\n

\n4,444<\/p>\n<\/td>\n

\n

\n12<\/p>\n<\/td>\n

\n

\n4,303<\/p>\n<\/td>\n

\n

\n15<\/p>\n<\/td>\n<\/tr>\n

\n

\nIndia<\/p>\n<\/td>\n

\n

\n12,834<\/p>\n<\/td>\n

\n

\n9,689<\/p>\n<\/td>\n

\n

\n32<\/p>\n<\/td>\n

\n

\n11,274<\/p>\n<\/td>\n

\n

\n14<\/p>\n<\/td>\n<\/tr>\n

\n

\nEmerging Markets<\/p>\n<\/td>\n

\n

\n11,142<\/p>\n<\/td>\n

\n

\n12,013<\/p>\n<\/td>\n

\n

\n(7)<\/p>\n<\/td>\n

\n

\n13,097<\/p>\n<\/td>\n

\n

\n(15)<\/p>\n<\/td>\n<\/tr>\n

\n

Pharmaceutical Services and Active Ingredients (PSAI)<\/b><\/p>\n<\/td>\n

\n

7,787<\/b><\/p>\n<\/td>\n

\n

7,557<\/b><\/p>\n<\/td>\n

\n

3<\/b><\/p>\n<\/td>\n

\n

7,758<\/b><\/p>\n<\/td>\n

\n

0<\/b><\/p>\n<\/td>\n<\/tr>\n

\n

Others<\/b><\/p>\n<\/td>\n

\n

924<\/b><\/p>\n<\/td>\n

\n

693<\/b><\/p>\n<\/td>\n

\n

33<\/b><\/p>\n<\/td>\n

\n

701<\/b><\/p>\n<\/td>\n

\n

32<\/b><\/p>\n<\/td>\n<\/tr>\n

\n

Total<\/b><\/p>\n<\/td>\n

\n

62,968<\/b><\/p>\n<\/td>\n

\n

54,368<\/b><\/p>\n<\/td>\n

\n

16<\/b><\/p>\n<\/td>\n

\n

67,700<\/b><\/p>\n<\/td>\n

\n

(7)<\/b><\/p>\n<\/td>\n<\/tr>\n<\/table>\n

All amounts in millions, except EPS. All US dollar amounts based on convenience translation rate of 1 USD = Rs. 82.19<\/i><\/p>\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n
\n

Dr. Reddy\u2019s Laboratories Limited and Subsidiaries<\/span><\/b><\/p>\n

Consolidated Income Statement<\/b><\/p>\n<\/td>\n<\/tr>\n

\n\n\n\u00a0<\/td>\n<\/tr>\n
\n

Particulars<\/b><\/p>\n<\/td>\n

\n

FY23<\/b><\/p>\n<\/td>\n

\n

FY22<\/b><\/p>\n<\/td>\n

\n

Gr<\/b><\/p>\n

%<\/b><\/p>\n<\/td>\n<\/tr>\n

\n

($)<\/b><\/p>\n<\/td>\n

\n

(Rs.)<\/b><\/p>\n<\/td>\n

\n

\n%<\/p>\n<\/td>\n

\n

($)<\/b><\/p>\n<\/td>\n

\n

(Rs.)<\/b><\/p>\n<\/td>\n

\n

\n%<\/p>\n<\/td>\n<\/tr>\n

\n

Revenue<\/b><\/p>\n<\/td>\n

\n

2,992<\/b><\/p>\n<\/td>\n

\n

2,45,879<\/b><\/p>\n<\/td>\n

\n

100.0<\/b><\/p>\n<\/td>\n

\n

2,608<\/b><\/p>\n<\/td>\n

\n

2,14,391<\/b><\/p>\n<\/td>\n

\n

100.0<\/b><\/p>\n<\/td>\n

\n

15<\/b><\/p>\n<\/td>\n<\/tr>\n

\n

\nCost of revenues<\/p>\n<\/td>\n

\n

\n1,296<\/p>\n<\/td>\n

\n

\n1,06,536<\/p>\n<\/td>\n

\n

\n43.3<\/p>\n<\/td>\n

\n

\n1,223<\/p>\n<\/td>\n

\n

\n1,00,551<\/p>\n<\/td>\n

\n

\n46.9<\/p>\n<\/td>\n

\n

\n6<\/p>\n<\/td>\n<\/tr>\n

\n

Gross profit<\/b><\/p>\n<\/td>\n

\n

1,695<\/b><\/p>\n<\/td>\n

\n

1,39,343<\/b><\/p>\n<\/td>\n

\n

56.7<\/b><\/p>\n<\/td>\n

\n

1,385<\/b><\/p>\n<\/td>\n

\n

1,13,840<\/b><\/p>\n<\/td>\n

\n

53.1<\/b><\/p>\n<\/td>\n

\n

22<\/b><\/p>\n<\/td>\n<\/tr>\n

\n

Operating Expenses<\/b><\/p>\n<\/td>\n

\n

\n\u00a0<\/p>\n<\/td>\n

\n

\n\u00a0<\/p>\n<\/td>\n

\n

\n\u00a0<\/p>\n<\/td>\n

\n

\n\u00a0<\/p>\n<\/td>\n

\n

\n\u00a0<\/p>\n<\/td>\n

\n

\n\u00a0<\/p>\n<\/td>\n

\n

\n\u00a0<\/p>\n<\/td>\n<\/tr>\n

\n

\nSelling, General & Administrative expenses<\/p>\n<\/td>\n

\n

\n828<\/p>\n<\/td>\n

\n

\n68,026<\/p>\n<\/td>\n

\n

\n27.7<\/p>\n<\/td>\n

\n

\n755<\/p>\n<\/td>\n

\n

\n62,081<\/p>\n<\/td>\n

\n

\n29.0<\/p>\n<\/td>\n

\n

\n10<\/p>\n<\/td>\n<\/tr>\n

\n

\nResearch and Development expenses<\/p>\n<\/td>\n

\n

\n236<\/p>\n<\/td>\n

\n

\n19,381<\/p>\n<\/td>\n

\n

\n7.9<\/p>\n<\/td>\n

\n

\n213<\/p>\n<\/td>\n

\n

\n17,482<\/p>\n<\/td>\n

\n

\n8.2<\/p>\n<\/td>\n

\n

\n11<\/p>\n<\/td>\n<\/tr>\n

\n

\nImpairment of non-current assets<\/p>\n<\/td>\n

\n

\n9<\/p>\n<\/td>\n

\n

\n699<\/p>\n<\/td>\n

\n

\n0.3<\/p>\n<\/td>\n

\n

\n92<\/p>\n<\/td>\n

\n

\n7,562<\/p>\n<\/td>\n

\n

\n3.5<\/p>\n<\/td>\n

\n

\n(91)<\/p>\n<\/td>\n<\/tr>\n

\n

\nOther operating income<\/p>\n<\/td>\n

\n

\n(72)<\/p>\n<\/td>\n

\n

\n(5,907)<\/p>\n<\/td>\n

\n

\n(2.4)<\/p>\n<\/td>\n

\n

\n(34)<\/p>\n<\/td>\n

\n

\n(2,761)<\/p>\n<\/td>\n

\n

\n(1.3)<\/p>\n<\/td>\n

\n

\n114<\/p>\n<\/td>\n<\/tr>\n

\n

Results from operating activities<\/b><\/p>\n<\/td>\n

\n

695<\/b><\/p>\n<\/td>\n

\n

57,144<\/b><\/p>\n<\/td>\n

\n

23.2<\/b><\/p>\n<\/td>\n

\n

359<\/b><\/p>\n<\/td>\n

\n

29,476<\/b><\/p>\n<\/td>\n

\n

13.7<\/b><\/p>\n<\/td>\n

\n

94<\/b><\/p>\n<\/td>\n<\/tr>\n

\n

\nNet finance income<\/p>\n<\/td>\n

\n

\n(35)<\/p>\n<\/td>\n

\n

\n(2,853)<\/p>\n<\/td>\n

\n

\n(1.2)<\/p>\n<\/td>\n

\n

\n(26)<\/p>\n<\/td>\n

\n

\n(2,119)<\/p>\n<\/td>\n

\n

\n(1.0)<\/p>\n<\/td>\n

\n

\n35<\/p>\n<\/td>\n<\/tr>\n

\n

\nShare of profit of equity accounted investees<\/p>\n<\/td>\n

\n

\n(5)<\/p>\n<\/td>\n

\n

\n(370)<\/p>\n<\/td>\n

\n

\n(0.2)<\/p>\n<\/td>\n

\n

\n(9)<\/p>\n<\/td>\n

\n

\n(703)<\/p>\n<\/td>\n

\n

\n(0.3)<\/p>\n<\/td>\n

\n

\n(47)<\/p>\n<\/td>\n<\/tr>\n

\n

Profit before income tax<\/b><\/p>\n<\/td>\n

\n

734<\/b><\/p>\n<\/td>\n

\n

60,367<\/b><\/p>\n<\/td>\n

\n

24.6<\/b><\/p>\n<\/td>\n

\n

393<\/b><\/p>\n<\/td>\n

\n

32,298<\/b><\/p>\n<\/td>\n

\n

15.1<\/b><\/p>\n<\/td>\n

\n

87<\/b><\/p>\n<\/td>\n<\/tr>\n

\n

\nIncome tax expense<\/p>\n<\/td>\n

\n

\n186<\/p>\n<\/td>\n

\n

\n15,300<\/p>\n<\/td>\n

\n

\n6.2<\/p>\n<\/td>\n

\n

\n106<\/p>\n<\/td>\n

\n

\n8,730<\/p>\n<\/td>\n

\n

\n4.1<\/p>\n<\/td>\n

\n

\n75<\/p>\n<\/td>\n<\/tr>\n

\n

Profit for the period<\/b><\/p>\n<\/td>\n

\n

548<\/b><\/p>\n<\/td>\n

\n

45,067<\/b><\/p>\n<\/td>\n

\n

18.3<\/b><\/p>\n<\/td>\n

\n

287<\/b><\/p>\n<\/td>\n

\n

23,568<\/b><\/p>\n<\/td>\n

\n

11.0<\/b><\/p>\n<\/td>\n

\n

91<\/b><\/p>\n<\/td>\n<\/tr>\n

\n\n

\n\u00a0<\/p>\n<\/td>\n

\n

\n\u00a0<\/p>\n<\/td>\n

\n

\n\u00a0<\/p>\n<\/td>\n

\n

\n\u00a0<\/p>\n<\/td>\n

\n

\n\u00a0<\/p>\n<\/td>\n

\n

\n\u00a0<\/p>\n<\/td>\n

\n

\n\u00a0<\/p>\n<\/td>\n<\/tr>\n

\n

Diluted EPS<\/b><\/p>\n<\/td>\n

\n

3.30<\/b><\/p>\n<\/td>\n

\n

270.85<\/b><\/p>\n<\/td>\n

\n

\n\u00a0<\/p>\n<\/td>\n

\n

1.72<\/b><\/p>\n<\/td>\n

\n

141.69<\/b><\/p>\n<\/td>\n

\n

\n\u00a0<\/p>\n<\/td>\n

\n

91<\/b><\/p>\n<\/td>\n<\/tr>\n<\/table>\n\n\n\n\n\n\n\n\n\n\n\n\n
\n

EBITDA Computation<\/b><\/p>\n<\/td>\n<\/tr>\n

\n\n\u00a0<\/td>\n<\/tr>\n
\n

Particulars<\/b><\/p>\n<\/td>\n

\n

FY23<\/b><\/p>\n<\/td>\n

\n

FY22<\/b><\/p>\n<\/td>\n<\/tr>\n

\n

($)<\/b><\/p>\n<\/td>\n

\n

(Rs.)<\/b><\/p>\n<\/td>\n

\n

($)<\/b><\/p>\n<\/td>\n

\n

(Rs.)<\/b><\/p>\n<\/td>\n<\/tr>\n

\n

Profit before Income Tax<\/b><\/p>\n<\/td>\n

\n

\n734<\/p>\n<\/td>\n

\n

\n60,367<\/p>\n<\/td>\n

\n

\n393<\/p>\n<\/td>\n

\n

\n32,298<\/p>\n<\/td>\n<\/tr>\n

\n

\nInterest income – Net*<\/p>\n<\/td>\n

\n

\n(8)<\/p>\n<\/td>\n

\n

\n(621)<\/p>\n<\/td>\n

\n

\n(3)<\/p>\n<\/td>\n

\n

\n(284)<\/p>\n<\/td>\n<\/tr>\n

\n

\nDepreciation<\/p>\n<\/td>\n

\n

\n105<\/p>\n<\/td>\n

\n

\n8,614<\/p>\n<\/td>\n

\n

\n99<\/p>\n<\/td>\n

\n

\n8,152<\/p>\n<\/td>\n<\/tr>\n

\n

\nAmortization<\/p>\n<\/td>\n

\n

\n49<\/p>\n<\/td>\n

\n

\n4,022<\/p>\n<\/td>\n

\n

\n45<\/p>\n<\/td>\n

\n

\n3,672<\/p>\n<\/td>\n<\/tr>\n

\n

\nImpairment<\/p>\n<\/td>\n

\n

\n9<\/p>\n<\/td>\n

\n

\n699<\/p>\n<\/td>\n

\n

\n92<\/p>\n<\/td>\n

\n

\n7,562<\/p>\n<\/td>\n<\/tr>\n

\n

EBITDA<\/b><\/p>\n<\/td>\n

\n

889<\/b><\/p>\n<\/td>\n

\n

73,081<\/b><\/p>\n<\/td>\n

\n

625<\/b><\/p>\n<\/td>\n

\n

51,400<\/b><\/p>\n<\/td>\n<\/tr>\n

\n

* Includes income from Investments<\/i><\/p>\n<\/td>\n

\n\n\n<\/tr>\n<\/table>\n\n\n\n\n\n\n\n\n\n\n\n\n\n
\n

Key Balance Sheet Items<\/b><\/p>\n<\/td>\n<\/tr>\n

\n\n\n\u00a0<\/td>\n<\/tr>\n
\n

Particulars<\/b><\/p>\n<\/td>\n

\n

As on 31st Mar 2023<\/b><\/p>\n<\/td>\n

\n

As on 31st Dec 2022<\/b><\/p>\n<\/td>\n

\n

As on 31st Mar 2022<\/b><\/p>\n<\/td>\n<\/tr>\n

\n

($)<\/b><\/p>\n<\/td>\n

\n

(Rs.)<\/b><\/p>\n<\/td>\n

\n

($)<\/b><\/p>\n<\/td>\n

\n

(Rs.)<\/b><\/p>\n<\/td>\n

\n

($)<\/b><\/p>\n<\/td>\n

\n

(Rs.)<\/b><\/p>\n<\/td>\n<\/tr>\n

\n

\nCash and cash equivalents and other investments<\/p>\n<\/td>\n

\n

\n760<\/p>\n<\/td>\n

\n

\n62,456<\/p>\n<\/td>\n

\n

\n610<\/p>\n<\/td>\n

\n

\n50,164<\/p>\n<\/td>\n

\n

\n584<\/p>\n<\/td>\n

\n

\n48,033<\/p>\n<\/td>\n<\/tr>\n

\n

\nTrade receivables (current & non-current)<\/p>\n<\/td>\n

\n

\n882<\/p>\n<\/td>\n

\n

\n72,486<\/p>\n<\/td>\n

\n

\n913<\/p>\n<\/td>\n

\n

\n75,046<\/p>\n<\/td>\n

\n

\n813<\/p>\n<\/td>\n

\n

\n66,818<\/p>\n<\/td>\n<\/tr>\n

\n

\nInventories<\/p>\n<\/td>\n

\n

\n592<\/p>\n<\/td>\n

\n

\n48,670<\/p>\n<\/td>\n

\n

\n600<\/p>\n<\/td>\n

\n

\n49,326<\/p>\n<\/td>\n

\n

\n619<\/p>\n<\/td>\n

\n

\n50,884<\/p>\n<\/td>\n<\/tr>\n

\n

\nProperty, plant and equipment<\/p>\n<\/td>\n

\n

\n809<\/p>\n<\/td>\n

\n

\n66,462<\/p>\n<\/td>\n

\n

\n791<\/p>\n<\/td>\n

\n

\n64,996<\/p>\n<\/td>\n

\n

\n756<\/p>\n<\/td>\n

\n

\n62,169<\/p>\n<\/td>\n<\/tr>\n

\n

\nGoodwill and Other Intangible assets<\/p>\n<\/td>\n

\n

\n427<\/p>\n<\/td>\n

\n

\n35,094<\/p>\n<\/td>\n

\n

\n431<\/p>\n<\/td>\n

\n

\n35,401<\/p>\n<\/td>\n

\n

\n385<\/p>\n<\/td>\n

\n

\n31,664<\/p>\n<\/td>\n<\/tr>\n

\n

\nLoans and borrowings (current & non-current)<\/p>\n<\/td>\n

\n

\n164<\/p>\n<\/td>\n

\n

\n13,472<\/p>\n<\/td>\n

\n

\n215<\/p>\n<\/td>\n

\n

\n17,663<\/p>\n<\/td>\n

\n

\n412<\/p>\n<\/td>\n

\n

\n33,845<\/p>\n<\/td>\n<\/tr>\n

\n

\nTrade payables<\/p>\n<\/td>\n

\n

\n322<\/p>\n<\/td>\n

\n

\n26,444<\/p>\n<\/td>\n

\n

\n317<\/p>\n<\/td>\n

\n

\n26,023<\/p>\n<\/td>\n

\n

\n311<\/p>\n<\/td>\n

\n

\n25,572<\/p>\n<\/td>\n<\/tr>\n

\n

\nEquity<\/p>\n<\/td>\n

\n

\n2,810<\/p>\n<\/td>\n

\n

\n2,30,991<\/p>\n<\/td>\n

\n

\n2,680<\/p>\n<\/td>\n

\n

\n2,20,273<\/p>\n<\/td>\n

\n

\n2,318<\/p>\n<\/td>\n

\n

\n1,90,527<\/p>\n<\/td>\n<\/tr>\n<\/table>\n

All amounts in millions, except EPS. All US dollar amounts based on convenience translation rate of 1 USD = Rs. 82.19<\/i><\/p>\n\n\n\n\n\n\n\n\n\n\n\n\n\n
\n

Revenue Mix by Segment [year on year]<\/b><\/p>\n<\/td>\n<\/tr>\n

\n\n\n\u00a0<\/td>\n<\/tr>\n
\n

Segment<\/b><\/p>\n<\/td>\n

\n

FY23<\/b><\/p>\n<\/td>\n

\n

FY22<\/b><\/p>\n<\/td>\n

\n

Gr<\/b><\/p>\n

%<\/b><\/p>\n<\/td>\n<\/tr>\n

\n

($)<\/b><\/p>\n<\/td>\n

\n

(Rs.)<\/b><\/p>\n<\/td>\n

\n

%<\/b><\/p>\n<\/td>\n

\n

($)<\/b><\/p>\n<\/td>\n

\n

(Rs.)<\/b><\/p>\n<\/td>\n

\n

%<\/b><\/p>\n<\/td>\n<\/tr>\n

\n

Global Generics<\/b><\/p>\n<\/td>\n

\n

2,601<\/b><\/p>\n<\/td>\n

\n

2,13,768<\/b><\/p>\n<\/td>\n

\n

86.9%<\/b><\/p>\n<\/td>\n

\n

2,180<\/b><\/p>\n<\/td>\n

\n

1,79,170<\/b><\/p>\n<\/td>\n

\n

83.6%<\/b><\/p>\n<\/td>\n

\n

19%<\/b><\/p>\n<\/td>\n<\/tr>\n

\n

\nNorth America<\/p>\n<\/td>\n

\n

\n1,237<\/p>\n<\/td>\n

\n

\n1,01,704<\/p>\n<\/td>\n

\n

\n41.4%<\/p>\n<\/td>\n

\n

\n911<\/p>\n<\/td>\n

\n

\n74,915<\/p>\n<\/td>\n

\n

\n34.9%<\/p>\n<\/td>\n

\n

\n36%<\/p>\n<\/td>\n<\/tr>\n

\n

\nEurope<\/p>\n<\/td>\n

\n

\n214<\/p>\n<\/td>\n

\n

\n17,603<\/p>\n<\/td>\n

\n

\n7.2%<\/p>\n<\/td>\n

\n

\n202<\/p>\n<\/td>\n

\n

\n16,631<\/p>\n<\/td>\n

\n

\n7.8%<\/p>\n<\/td>\n

\n

\n6%<\/p>\n<\/td>\n<\/tr>\n

\n

\nIndia<\/p>\n<\/td>\n

\n

\n595<\/p>\n<\/td>\n

\n

\n48,932<\/p>\n<\/td>\n

\n

\n19.9%<\/p>\n<\/td>\n

\n

\n510<\/p>\n<\/td>\n

\n

\n41,957<\/p>\n<\/td>\n

\n

\n19.6%<\/p>\n<\/td>\n

\n

\n17%<\/p>\n<\/td>\n<\/tr>\n

\n

\nEmerging Markets<\/p>\n<\/td>\n

\n

\n554<\/p>\n<\/td>\n

\n

\n45,529<\/p>\n<\/td>\n

\n

\n18.5%<\/p>\n<\/td>\n

\n

\n556<\/p>\n<\/td>\n

\n

\n45,667<\/p>\n<\/td>\n

\n

\n21.3%<\/p>\n<\/td>\n

\n

\n0%<\/p>\n<\/td>\n<\/tr>\n

\n

Pharmaceutical Services and Active Ingredients (PSAI)<\/b><\/p>\n<\/td>\n

\n

354<\/b><\/p>\n<\/td>\n

\n

29,069<\/b><\/p>\n<\/td>\n

\n

11.8%<\/b><\/p>\n<\/td>\n

\n

374<\/b><\/p>\n<\/td>\n

\n

30,740<\/b><\/p>\n<\/td>\n

\n

14.3%<\/b><\/p>\n<\/td>\n

\n

-5%<\/b><\/p>\n<\/td>\n<\/tr>\n

\n

Others<\/b><\/p>\n<\/td>\n

\n

37<\/b><\/p>\n<\/td>\n

\n

3,042<\/b><\/p>\n<\/td>\n

\n

1.2%<\/b><\/p>\n<\/td>\n

\n

55<\/b><\/p>\n<\/td>\n

\n

4,481<\/b><\/p>\n<\/td>\n

\n

2.1%<\/b><\/p>\n<\/td>\n

\n

-32%<\/b><\/p>\n<\/td>\n<\/tr>\n

\n

Total<\/b><\/p>\n<\/td>\n

\n

2,992<\/b><\/p>\n<\/td>\n

\n

2,45,879<\/b><\/p>\n<\/td>\n

\n

100.0%<\/b><\/p>\n<\/td>\n

\n

2,608<\/b><\/p>\n<\/td>\n

\n

2,14,391<\/b><\/p>\n<\/td>\n

\n

100.0%<\/b><\/p>\n<\/td>\n

\n

15%<\/b><\/p>\n<\/td>\n<\/tr>\n<\/table>\n

Revenue Analysis [Q4 FY23 and FY23]<\/b><\/p>\n

Global Generics (GG)<\/b><\/p>\n